Home/Pipeline/Undisclosed Novel Strategy

Undisclosed Novel Strategy

Type 1 Diabetes

Pre-clinicalEarly Research

Key Facts

Indication
Type 1 Diabetes
Phase
Pre-clinical
Status
Early Research
Company

About CG Scientific

CG Scientific Inc. is a private, early-stage biotech company dedicated to creating a breakthrough treatment for type 1 diabetes. The company operates from its headquarters in Worcester, Massachusetts, and is actively seeking investment opportunities to advance its novel therapeutic approach. While specific details about its technology platform and pipeline remain undisclosed on its public website, the company's mission centers on addressing the significant unmet medical need in autoimmune diabetes treatment. CG Scientific represents a promising venture in the competitive diabetes therapeutics landscape.

View full company profile

Other Type 1 Diabetes Drugs

DrugCompanyPhase
VX-880Vertex PharmaceuticalsPhase 1/2
VCTX210 (Vertex collab.)CRISPR TherapeuticsPhase 1/2
UP421Sana BiotechnologyPre-Clinical
SC451Sana BiotechnologyPre-Clinical
BioVascular Pancreas™HumacytePreclinical
ORMD-0801Oramed PharmaceuticalsPhase 2